2,2'-联-1,4-二恶烷 | 14230-41-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二恶烷
• 中文名称: 2,2'-联-1,4-二恶烷
• 英文名称: 2,2'-bi(1,4-dioxane)
• 英文别名: 2,2'-Bis-p-dioxane；bi-1,4-dioxane；Racemat des dimeren Dioxans；(d,l)-Bi-1,4-dioxanyl；meso-Bis-(2-dioxanyl)；dl-Bis-(2-dioxanyl)；2,2'-Bi-1,4-dioxane；2-(1,4-dioxan-2-yl)-1,4-dioxane
• CAS: 14230-41-2
• 化学式: C₈H₁₄O₄
• 分子量: 174.197
• InChiKey: NVRGHQLYUVWKIR-UHFFFAOYSA-N

物化性质

• 沸点：
  267.5±35.0 °C(Predicted)
• 密度：
  1.155±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.7
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  36.9
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 海关编码：
  2934999090

反应信息

• 作为产物：
  描述：

  1,4-二氧六环 在 汞 作用下， 反应 24.0h， 生成 2,2'-联-1,4-二恶烷
  参考文献：
  名称：

  Making mercury-photosensitized dehydrodimerization into an organic synthetic method. Vapor-pressure selectivity and the behavior of functionalized substrates

  摘要：

  DOI：

  10.1021/ja00190a031

文献信息

• DESIGN, SYNTHESIS AND FUNCTIONAL CHARACTERIZATION OF ROTTLERIN ANALOGS
  申请人：KANTHASAMY ANUMANTHA G.

  公开号：US20110112182A1

  公开（公告）日：2011-05-12

  A method of synthesizing rottlerin analogs is described. The synthesis methods described are the first known method of synthesizing rottlerin analogs from commercially-available materials to produce cost effective analogs. Rottlerin analog structures made by the synthesis methods and methods of use for treating a neurological or inflammatory response mediated by protein kinase C (PKC) are further described.

  描述了一种合成罗特林类似物的方法。所描述的合成方法是从商业可获得的材料中合成罗特林类似物的首个已知方法，以生产具有成本效益的类似物。通过这些合成方法制备的罗特林类似物结构以及用于治疗由蛋白激酶C（PKC）介导的神经或炎症反应的方法也进一步描述了。
• Pyrazolo [1,5-A] pyrimidine adenosine A2a receptor antagonists
  申请人：Clasby C. Martin

  公开号：US20060135526A1

  公开（公告）日：2006-06-22

  Compounds having the structural formula I are disclosed, wherein A is alkylene, or optionally substituted arylene, cycloalkylene or heteroaryldiyl; X is —C(O)— or —S(O) 2 —; R 1 is alkyl or cycloalkyl; R 2 is hydrogen, halo or —CN; R 3 is hydrogen or alkyl; R 4 is hydrogen, alkyl, alkoxy, hydroxyalkyl, aminoalkyl-, cycloalkyl, heterocycloalkyl, heterocycloalkyl substituted by alkyl, optionally substituted arylalkyl or optionally substituted heteroarylalkyl; or R 3 and R 4 , form an optionally substituted 5-7 membered ring, said ring optionally comprising an additional heteroatom ring member; R 7 is alkyl, optionally substituted phenyl, optionally substituted heteroaryl, cycloalkyl, halo, morpholinyl, optionally substituted piperazinyl, or optionally substituted azacycloalkyl. Also disclosed is the use of the compounds in the treatment of Parkinson's disease, alone or in combination with other agents for treating Parkinson's disease, pharmaceutical compositions comprising them and kits comprising the components of the combinations.

  揭示了具有结构式I的化合物，其中A是烷基，或者可选择地取代的芳基，环烷基或杂芳基二基；X是—C(O)—或—S(O)2—；R1是烷基或环烷基；R2是氢，卤素或—CN；R3是氢或烷基；R4是氢，烷基，烷氧基，羟基烷基，氨基烷基，环烷基，杂环烷基，被烷基取代的杂环烷基，可选择地取代的芳基烷基或可选择地取代的杂芳基烷基；或者R3和R4形成一个可选择地取代的5-7成员环，所述环可选择地包含一个额外的杂原子环成员；R7是烷基，可选择地取代的苯基，可选择地取代的杂芳基，环烷基，卤素，吗啉基，可选择地取代的哌嗪基，或可选择地取代的氮杂环烷基。还揭示了这些化合物在帕金森病治疗中的用途，单独或与其他治疗帕金森病的药剂组合使用，包含它们的药物组合物和包含组合物组分的工具包。
• C-17 BICYCLIC AMINES OF TRITERPENOIDS WITH HIV MATURATION INHIBITORY ACTIVITY
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：US20130296554A1

  公开（公告）日：2013-11-07

  Compounds having drug and bio-affecting properties, their pharmaceutical compositions and methods of use are set forth. In particular, C-17 bicyclic amines of triterpenoids that possess unique antiviral activity are provided as HIV maturation inhibitors, as represented by compounds of Formulas I, II and III: These compounds are useful for the treatment of HIV and AIDS.

  具有药物和生物活性的化合物、其药物组合物及其使用方法在此予以说明。特别是，提供了具有独特抗病毒活性的C-17双环胺三萜类化合物，作为HIV成熟抑制剂，由公式I、II和III所示的化合物代表：这些化合物可用于治疗HIV和艾滋病。
• [EN] C-3 AND C-17 MODIFIED TRITERPENOIDS AS HIV-1 INHIBITORS<br/>[FR] TRITERPÉNOÏDES MODIFIÉS EN C-3 ET C-17 UTILISÉS COMME INHIBITEURS DU VIH-1
  申请人：VIIV HEALTHCARE UK (NO 5) LTD

  公开号：WO2017134596A1

  公开（公告）日：2017-08-10

  Compounds having drug and bio-affecting properties, their pharmaceutical compositions and methods of use are set forth. In particular, betulinic acid derivatives that possess unique antiviral activity are provided as HIV maturation inhibitors, as represented by compounds of Formula (I). These compounds are useful for the treatment of HIV and AIDS.

  具有药物和生物活性的化合物、其药物组合物及其用途被详细说明。特别是，提供了具有独特抗病毒活性的白桦酸衍生物，这些衍生物作为HIV成熟抑制剂，由公式(I)所示的化合物代表。这些化合物可用于治疗HIV和艾滋病。
• C-3 ALKYL AND ALKENYL MODIFIED BETULINIC ACID DERIVATIVES
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：US20140243298A1

  公开（公告）日：2014-08-28

  Compounds having drug and bio-affecting properties, their pharmaceutical compositions and methods of use are set forth. In particular, alkyl and alkenyl C-3 modified betulinic acid derivatives that possess unique antiviral activity are provided as HIV maturation inhibitors, as represented by compounds of Formulas I, II, III and IV: a compound of Formula I a compound of Formula II a compound of Formula III and a compound of Formula IV These compounds are useful for the treatment of HIV and AIDS.

  具有药物和生物影响特性的化合物，其药物组合物和使用方法已列出。具体来说，提供了具有独特抗病毒活性的烷基和烯基C-3修饰的苦参酸衍生物作为HIV成熟抑制剂，如公式I、II、III和IV所代表的化合物： 公式I的化合物 公式II的化合物 公式III的化合物 以及公式IV的化合物 这些化合物对治疗HIV和艾滋病有用。